BRIEF published on 07/18/2024 at 07:35, 4 months 3 days ago Nicox Provides Second Quarter 2024 Update Q2 2024 Financial Update Ophthalmology Nicox NCX 470
PRESS RELEASE published on 07/18/2024 at 07:30, 4 months 3 days ago Nicox Provides Second Quarter 2024 Update Nicox reports €1.6M revenue & €7.8M cash for Q2 2024, extending funds until Feb 2025. Focus on NCX 470 development & Denali trial progress. New Board members appointed Revenue Cash Position Nicox NCX 470 Denali Trial
BRIEF published on 07/16/2024 at 07:35, 4 months 5 days ago Nicox appoints Damian Marron Chairman of the Board of Directors Board Of Directors Ophthalmology Nicox Marc Le Bozec Damian Brown
PRESS RELEASE published on 07/16/2024 at 07:30, 4 months 5 days ago Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director Nicox appoints Damian Marron as Chair of the Board and Marc Le Bozec as Director. Experienced leaders join Nicox Board, Labbe and Kaplan step down. Strategic shift in leadership Board Of Directors Healthcare Nicox Damian Marron Marc Le Bozec
BRIEF published on 06/19/2024 at 07:35, 5 months 2 days ago Nicox succeeds in its capital increase of 3.3 million euros Increase In Capital Ophthalmology Nicox NCX 470 Ocumension Therapeutics
BRIEF published on 06/03/2024 at 07:35, 5 months 18 days ago Nicox SA Announces Voting Rights as of May 31, 2024 Euronext Growth Paris Share Capital Voting Rights AMF Nicox
PRESS RELEASE published on 06/03/2024 at 07:30, 5 months 18 days ago Number of voting rights as of May 31, 2024 Nicox SA monthly publication of the number of shares and voting rights. Details on market, ISIN code, and company's lead programs Voting Rights Shares Ophthalmology Monthly Publication Nicox SA
BRIEF published on 05/31/2024 at 07:35, 5 months 21 days ago Nicox is hosting a webcast for its shareholders on June 6, 2024 Shareholders Webcast Increase In Capital Ophthalmology Nicox
BRIEF published on 05/24/2024 at 07:35, 5 months 28 days ago Nicox: 2024 Ordinary Shareholder Meeting Scheduled for June 28th 2024 Shareholder Meeting Voting Process Ophthalmology Nicox
PRESS RELEASE published on 05/24/2024 at 07:30, 5 months 28 days ago Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024 Nicox convenes its 2024 Ordinary Shareholder Meeting on June 28th, 2024, in Sophia Antipolis, France. Shareholders can vote in person, by proxy, or online Shareholder Voting Nicox 2024 Ordinary Shareholder Meeting June 28 2024 Ophthalmology Company
Published on 11/21/2024 at 14:15, 19 minutes ago neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 34 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 34 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 34 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 14:16, 18 minutes ago EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 19 minutes ago ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 12:35, 1 hour 59 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 06:58, 7 hours 36 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 19 hours 14 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 49 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 49 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
